Effects of terguride on anterior pituitary function in parkinsonian patients treated with L-dopa: A double-blind study versus placebo

Clinical Neuropharmacology

Volumn 19, Issue 1, 1996, Pages 72-80

  Martignoni, E ^a   Horowski, R ^c   Liuzzi, A ^b   Costa, A ^a   Dallabonzana, D ^b   Cozzi, R ^b   Attanasio, R ^b   Rainer, E ^c   Nappi, G ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b OSPEDALE NIGUARDA CA GRANDA   (Italy)

^c BAYER PHARMA AG   (Germany)

Author keywords

Dopamine agonist; Growth hormone; Hypothalamus; Parkinson's disease; Pituitary; Prolactin; Terguride; Thyroid stimulating hormone

Indexed keywords

CARBIDOPA; GROWTH HORMONE; LEVODOPA; PROLACTIN; SOMATOMEDIN C; TERGURIDE; THYROTROPIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOPAMINERGIC ACTIVITY; DOUBLE BLIND PROCEDURE; FEMALE; GROWTH HORMONE RELEASE; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; LONG TERM CARE; MALE; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PRIORITY JOURNAL; PROLACTIN RELEASE; RANDOMIZED CONTROLLED TRIAL; THYROTROPIN RELEASE;

EID: 0030051442     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-199619010-00006     Document Type: Article

References (25)

1. Marsden CD. Parkinson's disease. Lancet 1990;i:948-52.
2. Vogel HP, Ketsche R. Effect of hypoglycaemia, TRH and levodopa on plasma growth hormone, prolactin, thyrotropin and cortisol in Parkinson's disease before and during therapy. J Neural 1986;233:149-52.
3. Conte-Devolx B, Pfister B, Viallet F, Rey M, Conte-Devolx J. La fonction endocrine anté-hypophysaire dans la maladie de Parkinson. Presse Med 1987;16:566-8.
4. Franceschi M, Camerlingo M, Perego L, Bottacchi E, Truci G, Mamoli A. Tuberoinfundibular dopaminergic function in Parkinson's disease. Eur Neurol 1988;28:117-19.
5. Matzuk MM, Saper CB. Preservation of hypothalamic dopaminergic neurons in Parkinson's disease. Ann Neurol 1985;18:552-5.
6. Calne DB. Treatment of Parkinson's disease. N Engl J Med 1993;329:1021-7.
7. Wachtel H. Central dopaminergic and antidopaminergic effects of ergot derivatives structurally related to lisuride. In: Calne DB, Horowski R, McDonald RJ, Wuttke W, eds. Lisuride and other dopamine agonists. New York: Raven Press. 1983:64-72.
8. Kehr W, Wachtel H, Schneider HH. Dopaminergic and antidopaminergic properties of ergolines structurally related to lisuride. Dopamine receptor agonists proceedings 2. Acta Pharm Suec 1983;(suppl 2):98-110.
9. Wachtel H, Dorow R. Dual action on central dopamine function of transdihydrolisuride, a 9,10-dehydrogenated analogue of the ergot dopamine agonist lisuride. Life Sci 1983;32:421-32.
10. 2-autoreceptor agonists, with special reference to indolylbutylamines. Drugs Future 1990;15:819-32.
11. Brücke T, Bankiewicz K, Harvey-White J, Kopin I. The partial dopamine receptor agonist terguride in the MPTP-induced hemiparkinsonian monkey model. Eur Pharmacol 1988;148:445-8.
12. Lange KW, Löschmann PA, Wachtel H, et al. Teguride stimulates locomotor activity at 2 month but not 10 month after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment of common marmosets. Eur J Pharmacol 1992;212:247-52.
13. Dallabonzana D, Liuzzi A, Oppizzi G, et al. Effect of the new ergot derivative terguride on plasma PRL and GH levels in patients with pathological hyperprolactinemia or acromegaly. J Endocrinol Invest 1985;8:147-52.
14. Schopohl J, Losa M, König A. Müller OA, Stalla GK, von Werder K. Combined pituitary function-test with four hypothalamic releasing hormones. Klin Wochenschr 1986;64:314-18.
15. Venturini PL, Horowski R, Fasce V, et al. Suppression of puerperal lactation by terguride. Gynecol Obstet Invest 1988;26:33-8.
16. von Werder K, Gräf KJ, Scholz A, Horowski R. Therapy with the new partial dopamine agonist terguride. Nichidoku-Iho 1989;33:189-200.
17. Carlsson M, Carlsson A, Eriksson E. The intrinsic activities of the partial dopamine receptor agonists (-)-3-PPP and TDHL on pituitary dopamine receptors are lower in female than in male rats. Eur Pharmacol 1987;142:39-43.
18. Ciccarelli MD, Touzel R, Besser M, Grossman A. Terguride - a new dopamine agonist drug: a comparison of its neuroendocrine and side effect profile with bromocriptine. Fertil Steril 1986;32:64-9.
19. Horowski R, Graf KJ. Influence of dopaminergic agonists and antagonists on serum prolactin concentrations in the rat. Neuroendocrinology 1976;22:273-86.
20. Fine SA, Frohman LA. Loss of central nervous system component of dopaminergic inhibition of prolactin secretion in patients with prolactin-secreting pituitary tumors. J Clin Invest 1978;61:973-80.
21. Koller WC, Herbster G. Terguride, a mixed dopamine agonist-antagonist in animal models of Parkinson's disease. Neurology 1987;37:723-7.
22. Baronti F, Mouradian MM, Conant KE, Giuffra M, Brughitta G, Chase TN. Partial dopamine agonist therapy of levodopa-induced dyskinesias. Neurology 1992;42:1241-3.
23. Corsini GU, Bonuccelli U, Rainer E, Del Zompo M. Therapeutic efficacy of a partial dopamine agonist in drug-free parkinsonian patients. J Neurol Transm 1985;65:105-11.
24. Critchley P, Parkes D. Transdihydrolisuride in parkinsonism. Clin Neuropharmacol 1987;10:57-64.
25. Pacchetti C, Martignoni E, Bruggi P. et al. Terguride in fluctuating parkinsonian patients: a double-blind study versus placebo. Mov Disord 1993;8:463-5.